Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.

NPJ vaccines·2023
Same author

Cerebellar Astrocyte Transduction as Gene Therapy for Megalencephalic Leukoencephalopathy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2020
Same author

Intracellular characterization of Gag VLP production by transient transfection of HEK 293 cells.

Biotechnology and bioengineering·2017
Same author

Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2017
Same author

β-Catenin and plakoglobin N- and C-tails determine ligand specificity.

The Journal of biological chemistry·2016
Same author

The transcriptional factor Tcf-4 contains different binding sites for β-catenin and plakoglobin.

The Journal of biological chemistry·2016

Related Experiment Video

Updated: May 6, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

6.8K

Canine adenovirus downstream processing protocol.

Meritxell Puig1, Jose Piedra, Susana Miravet

  • 1Department of Biochemistry and Molecular Biology, Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autonoma Barcelona, Bellaterra, Spain.

Methods in Molecular Biology (Clifton, N.J.)
|October 18, 2013
PubMed
Summary

Canine adenovirus type 2 (CAV-2) vectors offer an alternative to human adenovirus vectors due to pre-existing immunity. This study details a scalable GMP-compliant purification protocol for CAV-2 vectors, achieving high yields and purity.

More Related Videos

An Efficient Method for Adenovirus Production
10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

16.1K
Author Spotlight: Developing Gene Therapies for Muscular Dystrophies and Neuromuscular Disorders
05:03

Author Spotlight: Developing Gene Therapies for Muscular Dystrophies and Neuromuscular Disorders

Published on: August 23, 2024

2.8K

Related Experiment Videos

Last Updated: May 6, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

6.8K
An Efficient Method for Adenovirus Production
10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

16.1K
Author Spotlight: Developing Gene Therapies for Muscular Dystrophies and Neuromuscular Disorders
05:03

Author Spotlight: Developing Gene Therapies for Muscular Dystrophies and Neuromuscular Disorders

Published on: August 23, 2024

2.8K

Area of Science:

  • Gene Therapy
  • Virology
  • Biotechnology

Background:

  • Human adenovirus vectors face limitations due to pre-existing immunity in most adults.
  • Nonhuman adenovirus vectors, such as canine adenovirus type 2 (CAV-2), are being explored to overcome this challenge.
  • CAV-2 vectors show potential in treating neurodegenerative disorders, oncolytic virotherapy, and as vaccine vectors.

Purpose of the Study:

  • To develop and report a scalable Good Manufacturing Practice (GMP)-compliant downstream processing strategy for canine adenovirus type 2 (CAV-2) vectors.
  • To establish a robust purification protocol for high-quality CAV-2 vector preparations.

Main Methods:

  • Clarification using microfiltration.
  • Concentration and partial purification via ultrafiltration-diafiltration.
  • Removal of contaminating nucleic acids using Benzonase® digestion.
  • Two-step chromatography: propyl hydrophobic interaction chromatography (HIC) followed by DEAE anion exchange monoliths.

Main Results:

  • The protocol successfully clarifies, concentrates, and purifies CAV-2 particles.
  • High-quality vector preparations with minimal empty capsids and inactive forms were obtained.
  • The overall process yield ranged from 38-45%.

Conclusions:

  • A scalable and effective downstream processing strategy for CAV-2 vectors has been established.
  • This protocol facilitates the GMP-compliant production of high-purity CAV-2 vectors.
  • The developed method supports the clinical translation of CAV-2 vector-based therapies.